All In Biotech

Drug Trial Radar · NCT04042402

Long Term Extension Study in Patients With Primary Hyperoxaluria

An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria

Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Jul 9, 2019

Primary completion

Apr 1, 2030

Study completion Apr 1, 2030

Sponsor

Sponsor type
Industry
First posted
Aug 2, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The proposed study is designed to provide patients previously enrolled in Phase 1 and 2 studies of DCR-PHXC and their siblings (\<18 years old) long-term access to DCR-PHXC, and to evaluate the long-term safety and efficacy of DCR-PHXC in patients with PH.

Conditions

  • Primary Hyperoxaluria Type 1 (PH1)
  • Primary Hyperoxaluria Type 2 (PH2)
  • Kidney Diseases
  • Urologic Diseases
  • Genetic Disease
  • Primary Hyperoxaluria Type 3 (PH3)

Interventions

  • DCR-PHXCDrug

    Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The annual rate of decline in eGFR in participants with PH1Time frame: Annual change from baseline

Locations

23 sites in 13 countries. Site status is shown where the registry gives one.

  • Clinical Research Site

    San Francisco, California

  • Clinical Trial Site

    Boston, Massachusetts

  • Clinical Trial Site

    Rochester, Minnesota

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    Melbourne, Australia

  • Clinical Research Site

    Herston, Queensland, Australia

  • Clinical Research Site

    Hamilton, Ontario, Canada

  • Clinical Trial Site

    Bron, France

  • Clinical Trial Site

    Paris, France

  • Clinical Trial Site

    Bonn, Germany

  • Clinical Trial Site

    Heidelberg, Germany

  • Clinical Research Site

    Roma, Italy

  • Clinical Trial Site

    Fukuoka, Japan

  • Clinical Trial Site

    Nagoya, Japan

  • Clinical Trial Site

    Tokyo, Japan

  • Clinical Trial Site

    Beirut, Lebanon

  • Clinical Trial Site

    Amsterdam, Netherlands

  • Clinical Trial Site

    Tromsø, Norway

  • Clinical Research Site

    Barcelona, Spain

  • Clinical Trial Site

    Barcelona, Spain

  • Clinical Trial Site

    Ankara, Turkey (Türkiye)

  • Clinical Trial Site

    Birmingham, United Kingdom

  • Clinical Trial Site

    Hampstead, London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.